Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Disney CEO Bob Iger says the fierce competition for Warner Bros. Discovery highlights the 'tremendous value' of Disney's existing franchises, while reaffirming the company's focus on organic IP creation over further major acquisitions.
Shares of the packaged food giant have slumped over the past year, raising questions about whether the stock is a bargain or a value trap. A deep dive into valuation metrics suggests significant upside potential.
Despite a recent stock dip, ASML's record order book, driven by surging demand for advanced memory systems, points to sustained growth as AI and data center expansions create a 'perfect storm' for the lithography giant.
Shares of Canadian challenger bank EQB have delivered stellar long-term gains, significantly outperforming the broader market. While recent momentum has cooled, the stock's journey offers insights into the power of dividends and shifting market sentiment.
Investment firm Giverny Capital outlines its rationale for adding Watsco to its portfolio, highlighting a value-oriented strategy as markets remain dominated by AI euphoria. The firm's latest investor letter reveals a challenging quarter of narrow returns.
A recent anniversary event for 'Silicon Alley' highlighted how New York's technology sector has evolved from a concentrated downtown community into a vast, decentralized force spanning finance, AI, and e-commerce.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
A convoy of Syrian government forces was observed moving toward the strategic northeastern city of Hasakah on Monday, implementing a ceasefire agreement that aims to reintegrate Kurdish-administered territories with Damascus.
Precious metals extended their sharp decline following President Trump's nomination for the next Federal Reserve chair, a move markets interpret as locking in higher interest rates and boosting the U.S. dollar's appeal.
While Tesla's stock remains resilient, the promise of a self-driving future presents both staggering potential and significant hurdles for investors to consider.
A sharp $250 billion sell-off across cryptocurrency markets this weekend has been attributed by analysts to a tightening of U.S. dollar liquidity, driven by macro fiscal pressures, rather than a fundamental failure of digital assets.
The asset manager declares a $0.03 per share payout, with its dividend yield sitting below industry average as a rising stock price and robust earnings growth paint a complex picture for income-focused investors.
Japanese apparel retailer Shimamura (TSE:8227) has completed a massive share repurchase program and reshuffled its executive team in a concentrated two-day move, signaling a strategic pivot to boost per-share metrics and long-term value.
A new poll shows the centre-right Tisza party maintaining an eight-point advantage over the ruling Fidesz, setting the stage for Hungary's most consequential vote in over a decade, with major implications for Europe's political landscape.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
